Rep. April McClain Delaney Buys Laboratory Co. of America Holdings (NYSE:LH) Shares

Representative April McClain Delaney (D-Maryland) recently bought shares of Laboratory Co. of America Holdings (NYSE:LH). In a filing disclosed on March 20th, the Representative disclosed that they had bought between $1,001 and $15,000 in Laboratory Co. of America stock on February 28th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Revvity (NYSE:RVTY) on 2/28/2025.
• Purchased $15,001 – $50,000 in shares of Corpay (NYSE:CPAY) on 2/28/2025.
• Sold $1,001 – $15,000 in shares of Tempur Sealy International (NYSE:TPX) on 2/28/2025.
• Purchased $1,001 – $15,000 in shares of CACI International (NYSE:CACI) on 2/27/2025.
• Purchased $1,001 – $15,000 in shares of Laboratory Co. of America (NYSE:LH) on 2/27/2025.
• Purchased $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/27/2025.
• Sold $15,001 – $50,000 in shares of Teledyne Technologies (NYSE:TDY) on 2/22/2025.
• Purchased $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 2/22/2025.
• Sold $1,001 – $15,000 in shares of Tempur Sealy International (NYSE:TPX) on 2/22/2025.
• Sold $1,001 – $15,000 in shares of CACI International (NYSE:CACI) on 2/22/2025.

Laboratory Co. of America Stock Performance

NYSE LH opened at $233.97 on Friday. The firm’s fifty day moving average price is $245.16 and its two-hundred day moving average price is $234.31. The stock has a market cap of $19.58 billion, a PE ratio of 26.53, a PEG ratio of 1.71 and a beta of 1.12. Laboratory Co. of America Holdings has a fifty-two week low of $191.97 and a fifty-two week high of $258.59. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44.

Laboratory Co. of America (NYSE:LH) last posted its earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. On average, equities analysts expect that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th were paid a dividend of $0.72 per share. The ex-dividend date was Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.23%. Laboratory Co. of America’s payout ratio is presently 32.65%.

Institutional Investors Weigh In On Laboratory Co. of America

Several hedge funds and other institutional investors have recently made changes to their positions in LH. Empowered Funds LLC increased its position in shares of Laboratory Co. of America by 8.2% during the third quarter. Empowered Funds LLC now owns 7,982 shares of the medical research company’s stock worth $1,784,000 after acquiring an additional 608 shares in the last quarter. Mutual of America Capital Management LLC bought a new stake in shares of Laboratory Co. of America during the third quarter worth about $2,316,000. Claro Advisors LLC bought a new stake in shares of Laboratory Co. of America during the third quarter worth about $277,000. Swiss National Bank increased its position in shares of Laboratory Co. of America by 0.5% during the third quarter. Swiss National Bank now owns 250,220 shares of the medical research company’s stock worth $55,919,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Aviance Capital Partners LLC increased its position in shares of Laboratory Co. of America by 14.0% during the third quarter. Aviance Capital Partners LLC now owns 4,396 shares of the medical research company’s stock worth $982,000 after acquiring an additional 539 shares in the last quarter. 95.94% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LH has been the topic of several analyst reports. Piper Sandler boosted their price objective on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Morgan Stanley boosted their target price on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Evercore ISI upgraded shares of Laboratory Co. of America from an “in-line” rating to an “outperform” rating and boosted their target price for the company from $260.00 to $265.00 in a report on Tuesday, January 7th. Citigroup upgraded shares of Laboratory Co. of America from a “neutral” rating to a “buy” rating and boosted their target price for the company from $250.00 to $300.00 in a report on Tuesday, March 4th. Finally, StockNews.com upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Laboratory Co. of America has a consensus rating of “Moderate Buy” and a consensus target price of $268.38.

Insiders Place Their Bets

In other Laboratory Co. of America news, CMO Amy B. Summy sold 226 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $250.40, for a total value of $56,590.40. Following the completion of the sale, the chief marketing officer now directly owns 4,544 shares of the company’s stock, valued at approximately $1,137,817.60. This represents a 4.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Kerrii B. Anderson sold 500 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $255.63, for a total transaction of $127,815.00. Following the completion of the sale, the director now directly owns 13,166 shares of the company’s stock, valued at $3,365,624.58. The trade was a 3.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,500 shares of company stock valued at $3,577,572. Corporate insiders own 0.85% of the company’s stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.